Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Choice Between Advanced Therapies for Parkinson’s Disease Patients: Why, What, and When?
Joke M. Dijk, Alberto J. Espay, Regina Katzenschlager, et al.
Journal of Parkinson s Disease (2020) Vol. 10, Iss. s1, pp. S65-S73
Open Access | Times Cited: 55

Showing 1-25 of 55 citing articles:

COMT Inhibitors in the Management of Parkinson’s Disease
Margherita Fabbri, Joaquim J. Ferreira, Olivier Rascol
CNS Drugs (2022) Vol. 36, Iss. 3, pp. 261-282
Closed Access | Times Cited: 38
Current Treatments and New, Tentative Therapies for Parkinson’s Disease
Teresa Pardo-Moreno, Victoria García‐Morales, Nora Suleiman‐Martos, et al.
Pharmaceutics (2023) Vol. 15, Iss. 3, pp. 770-770
Open Access | Times Cited: 38
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study
Jason Aldred, Eric Freire‐Alvarez, А. В. Амелин, et al.
Neurology and Therapy (2023) Vol. 12, Iss. 6, pp. 1937-1958
Open Access | Times Cited: 36
Off-time Treatment Options for Parkinson’s Disease
Margherita Fabbri, Raquel Barbosa, Olivier Rascol
Neurology and Therapy (2023) Vol. 12, Iss. 2, pp. 391-424
Open Access | Times Cited: 29
Levodopa–Carbidopa–Entacapone Intestinal Gel in Advanced Parkinson Disease: A Multicenter Real-Life Experience
József Attila Szász, Adriana Octaviana Dulămea, Viorelia Constantin, et al.
American Journal of Therapeutics (2024)
Closed Access | Times Cited: 13
Unveiling the Unpredictable in Parkinson’s Disease: Sensor-Based Monitoring of Dyskinesias and Freezing of Gait in Daily Life
Alessandro Zampogna, Luigi Borzì, Domiziana Rinaldi, et al.
Bioengineering (2024) Vol. 11, Iss. 5, pp. 440-440
Open Access | Times Cited: 8
Next-Generation Cognitive-Behavioral Therapy for Depression: Integrating Digital Tools, Teletherapy, and Personalization for Enhanced Mental Health Outcomes
Evgenia Gkintoni, Stephanos P. Vassilopoulos, Γεώργιος Νικολάου
Medicina (2025) Vol. 61, Iss. 3, pp. 431-431
Open Access | Times Cited: 1
Autophagy-Lysosomal Pathway as Potential Therapeutic Target in Parkinson’s Disease
Srinivasa Reddy Bonam, Christine Tranchant, Sylviane Muller
Cells (2021) Vol. 10, Iss. 12, pp. 3547-3547
Open Access | Times Cited: 45
Genetic architecture of Parkinson’s disease subtypes – Review of the literature
Jarosław Dulski, Ryan J. Uitti, Owen A. Ross, et al.
Frontiers in Aging Neuroscience (2022) Vol. 14
Open Access | Times Cited: 34
Long-term effect of apomorphine infusion in advanced Parkinson’s disease: a real-life study
Bruna Meira, Bertrand Degos, Elise Corsetti, et al.
npj Parkinson s Disease (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 39
New approaches for developing multi-targeted drug combinations for disease modification of complex brain disorders. Does epilepsy prevention become a realistic goal?
Wolfgang Löscher, Pavel Klein
Pharmacology & Therapeutics (2021) Vol. 229, pp. 107934-107934
Open Access | Times Cited: 38
Infusion Therapies in the Treatment of Parkinson’s Disease
Teus van Laar, К. Ray Chaudhuri, Angelo Antonini, et al.
Journal of Parkinson s Disease (2023) Vol. 13, Iss. 5, pp. 641-657
Open Access | Times Cited: 14
Parkinson’s disease therapy: what lies ahead?
Andreas Wolff, Nicolas U Schumacher, Dominik Pürner, et al.
Journal of Neural Transmission (2023) Vol. 130, Iss. 6, pp. 793-820
Open Access | Times Cited: 13
Access to device-aided therapies in advanced Parkinson’s disease: navigating clinician biases, patient preference, and prognostic uncertainty
Manon Auffret, Daniel Weiß, Fabrizio Stocchi, et al.
Journal of Neural Transmission (2023) Vol. 130, Iss. 11, pp. 1411-1432
Open Access | Times Cited: 13
Treatment of Motor Symptoms of Parkinson’s Disease
Luca Marsili, Matteo Bologna, Lily Y. Chen, et al.
Neurologic Clinics (2025) Vol. 43, Iss. 2, pp. 341-363
Closed Access
Device-assisted therapies for Parkinson disease.
Nadia Mouchaileh, Jillian M. Cameron
PubMed (2025) Vol. 48, Iss. 1, pp. 10-17
Closed Access
Community-based exercise programming for individuals with Parkinson’s disease: a qualitative study
Aiza Khan, C Allyson Jones, Marguerite Wieler, et al.
Research Square (Research Square) (2025)
Closed Access
Parkinson's disease advanced therapies - A systematic review: More unanswered questions than guidance
Luca Marsili, Matteo Bologna, Janis M. Miyasaki, et al.
Parkinsonism & Related Disorders (2020) Vol. 83, pp. 132-139
Closed Access | Times Cited: 34
Current and novel infusion therapies for patients with Parkinson's disease
Angelo Antonini, Valentina D’Onofrio, Andrea Guerra
Journal of Neural Transmission (2023) Vol. 130, Iss. 11, pp. 1349-1358
Open Access | Times Cited: 12
New horizons in Parkinson’s disease in older populations
Jagadish K. Chhetri, Shanshan Mei, Chaodong Wang, et al.
Age and Ageing (2023) Vol. 52, Iss. 10
Closed Access | Times Cited: 11
Effective Management of “OFF” Episodes in Parkinson’s Disease: Emerging Treatment Strategies and Unmet Clinical Needs
Nbaa Masood, Joohi Jimenez‐Shahed
Neuropsychiatric Disease and Treatment (2023) Vol. Volume 19, pp. 247-266
Open Access | Times Cited: 9
Levodopa–Entacapone–Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease: A Single Center Real-World Experience
Szabolcs Szatmári, József Attila Szász, Károly Orbán-Kis, et al.
Pharmaceutics (2024) Vol. 16, Iss. 4, pp. 453-453
Open Access | Times Cited: 3
Continuous subcutaneous apomorphine infusion in the early phase of advanced Parkinson’s disease: A prospective study of 22 patients
Gustavo Fernández‐Pajarín, Ángel Sesar, Isabel Jiménez Martín, et al.
Clinical Parkinsonism & Related Disorders (2021) Vol. 6, pp. 100129-100129
Open Access | Times Cited: 21
Tratamiento farmacológico de los síntomas motores de la enfermedad de Parkinson: actualización y recomendaciones de un experto
Jaime Kulisevsky
Revista de Neurología (2022) Vol. 75, Iss. S04, pp. S1-S1
Open Access | Times Cited: 14
Advanced Parkinson’s disease treatment patterns in Italy: an observational study interim analysis
Fabrizio Stocchi, Paolo Barone, Roberto Ceravolo, et al.
Annals of Medicine (2024) Vol. 56, Iss. 1
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top